
CSL says it is paying $US200 million ($A312m) up-front to license next-generation mRNA vaccine technology from a small US company.
CSL said on Wednesday its CSL Seqirus subsidiary, the second-biggest flu vaccine manufacturer globally, has licensed the technology from NASDAQ-listed Arcturus Therapeutics.